Insensitivity to Scope in Contingent Valuation Studies Jennifer A. Whitty Editorial 12 December 2012 Pages: 361 - 363
Inclusion of Compliance and Persistence in Economic Models Ananth KadambiRobert J. LeipoldDenis Getsios Review Article 12 December 2012 Pages: 365 - 379
Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder M. Haim ErderJipan XieVanja Sikirica Original Research Article 12 December 2012 Pages: 381 - 395
Insensitivity to Scope in Contingent Valuation Studies Rikke SøgaardJes LindholtDorte Gyrd-Hansen Original Research Article 12 December 2012 Pages: 397 - 405
What Explains Willingness to Pay for Smoking-Cessation Treatments —Addiction Level, Quit-Rate Effectiveness or the Opening Bid? Jan Abel OlsenOle J. RøgebergKnut Stavem Original Research Article 12 December 2012 Pages: 407 - 415
Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain Tatiana DillaAmparo ValladaresMaría Costi Original Research Article Open access 12 December 2012 Pages: 417 - 430
Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome Michael EaddyBrian SealKen O’Day Original Research Article 12 December 2012 Pages: 431 - 440
Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing? Jaume Puig-Junoy Original Research Article 12 December 2012 Pages: 441 - 451